Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonnet Biotherapeutics Holdings Inc (NQ: SONN )

2.940 +0.020 (+0.68%)
Streaming Delayed Price Updated: 2:38 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,392
Open 2.880
Bid (Size) 2.940 (1)
Ask (Size) 2.990 (1)
Prev. Close 2.920
Today's Range 2.880 - 3.080
52wk Range 2.500 - 18.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga

Performance

YTD
-79.12%
-79.12%
1 Month
-48.51%
-48.51%
3 Month
-48.60%
-48.60%
6 Month
-78.88%
-78.88%
1 Year
-73.18%
-73.18%

More News

Read More
Dow Jumps Over 1,200 Points; Donald Trump Wins White House
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024
Via InvestorPlace
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
Dow Edges Lower; US Current Account Deficit Widens In Q1
Via Benzinga
Topics Stocks
Exposures US Equities
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Via ACCESSWIRE
SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024
Via InvestorPlace
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.